Skip to main content

Brukinsa Side Effects

Generic name: zanubrutinib

Medically reviewed by Last updated on Feb 28, 2022.

Note: This document contains side effect information about zanubrutinib. Some of the dosage forms listed on this page may not apply to the brand name Brukinsa.

For the Consumer

Applies to zanubrutinib: oral capsule

Side effects requiring immediate medical attention

Along with its needed effects, zanubrutinib (the active ingredient contained in Brukinsa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking zanubrutinib:

More common

  • Black, tarry stools
  • bladder pain
  • bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody or cloudy urine
  • blurred vision
  • body aches or pain
  • chest pain or tightness
  • chills
  • cough
  • coughing up blood
  • decreased urine
  • difficult, burning, or painful urination
  • difficulty in breathing or swallowing
  • dizziness
  • dry mouth
  • ear congestion
  • fast, slow, or irregular heartbeat
  • fever
  • frequent urge to urinate
  • headache
  • increased menstrual flow or vaginal bleeding
  • increased thirst
  • large, flat, blue, or purplish patches in the skin
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • mood changes
  • muscle pain or cramps
  • nausea or vomiting
  • nervousness
  • nosebleeds
  • numbness or tingling in the hands, feet, or lips
  • painful or difficult urination
  • pale skin
  • paralysis
  • pinpoint red spots on the skin
  • pounding in the ears
  • prolonged bleeding from cuts
  • runny or stuffy nose
  • seizures
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss

Side effects not requiring immediate medical attention

Some side effects of zanubrutinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to zanubrutinib: oral capsule


Very common (10% or more): All grades neutropenia (up to 56%), all grades thrombocytopenia (up to 45%) , hemorrhage (up to 32%), all grades anemia (up to 28%) , all grades leukopenia (25%)

Common (1% to 10%): Grade 3 or 4 anemia, Grade 3 or 4 leukopenia, Grade 3 or 4 thrombocytopenia[Ref]


Very common (10% or more): Grade 3 or higher infection (23%)[Ref]


Very common (10% or more): Musculoskeletal pain (e.g., musculoskeletal pain, musculoskeletal discomfort, myalgia, back pain, arthralgia, arthritis) (up to 45%), muscle spasms (10%)[Ref]


Very common (10% or more): Glucose increased (45%), blood uric acid increased (up to 29%), hypokalemia (14%), calcium decreased (27%), hyperkalemia (24%), hypophosphatemia (20%)


Very common (10% or more): Urinary tract infection (up to 15%)[Ref]


Very common (10% or more): ALT increased (28%), bilirubin increased (up to 24%)

Common (1% to 10%): Hepatitis B reactivation[Ref]


Very common (10% or more): Second primary malignancies (13%)[Ref]


Very common (10% or more): Upper respiratory tract infection (up to 44%), pneumonia (up to 22%), cough (up to 21%)[Ref]


Very common (10% or more): Hypertension (12%)

Common (1% to 10%): Atrial fibrillation, atrial flutter[Ref]


Very common (10% or more): Rash (up to 30%), bruising (up to 20%), pruritus (11%)[Ref]


Very common (10% or more): Diarrhea (up to 23%), constipation (up to 16%), nausea (18%)

Uncommon (0.1% to 1%): Gastrointestinal hemorrhage[Ref]


The most common adverse events were neutropenia, thrombocytopenia, upper respiratory tract infection, hemorrhage, rash, anemia and musculoskeletal pain.


Very common (10% or more): Creatinine increased (31%)


Very common (10% or more): Fatigue (up to 15%), peripheral edema (12%), pyrexia (16%)

Common (1% to 10%): Asthenia

Nervous system

Very common (10% or more): Dizziness (11%)

Frequently asked questions


1. "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.